178 related articles for article (PubMed ID: 20850091)
1. Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes.
Prati F; Capodanno D; Pawlowski T; Ramazzotti V; Albertucci M; La Manna A; Di Salvo M; Gil RJ; Tamburino C
JACC Cardiovasc Interv; 2010 Sep; 3(9):928-34. PubMed ID: 20850091
[TBL] [Abstract][Full Text] [Related]
2. ClearWayRX system to reduce intracoronary thrombus in patients with acute coronary syndromes according to optical coherence tomography after abciximab intracoronary local infusion trial (COCTAIL): study rationale and design.
Capodanno D; Prati F; Pawlowsky T; Ramazzotti V; Albertucci J; La Manna A; Robert G; Tamburino C
J Cardiovasc Med (Hagerstown); 2010 Feb; 11(2):130-6. PubMed ID: 19829141
[TBL] [Abstract][Full Text] [Related]
3. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction.
Gibson CM; Maehara A; Lansky AJ; Wohrle J; Stuckey T; Dave R; Cox D; Grines C; Dudek D; Steg G; Parise H; Wolff SD; Cristea E; Stone GW
Am Heart J; 2011 Mar; 161(3):478-486.e7. PubMed ID: 21392601
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of standard versus ClearWay-infused abciximab and thrombectomy in myocardial infarction: rationale and design of the COCTAIL II study.
Prati F; Di Vito L; Ramazzotti V; Imola F; Pawlowski T; Materia L; Tavazzi L; Biondi-Zoccai G; Albertucci M
J Cardiovasc Med (Hagerstown); 2013 May; 14(5):364-71. PubMed ID: 22929568
[TBL] [Abstract][Full Text] [Related]
7. Randomized evaluation of intralesion versus intracoronary abciximab and aspiration thrombectomy in patients with ST-elevation myocardial infarction: The COCTAIL II trial.
Prati F; Romagnoli E; Limbruno U; Pawlowski T; Fedele S; Gatto L; Di Vito L; Pappalardo A; Ramazzotti V; Picchi A; Trivisonno A; Materia L; Pfiatkosky P; Paoletti G; Marco V; Tavazzi L; Versaci F; Stone GW
Am Heart J; 2015 Dec; 170(6):1116-23. PubMed ID: 26678633
[TBL] [Abstract][Full Text] [Related]
8. A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale.
Sardella G; Sangiorgi GM; Mancone M; Colantonio R; Donahue M; Politi L; Bucciarelli-Ducci C; Carbone I; Francone M; Ligabue G; Fiocchi F; Di Roma A; Benedetti G; Lucisano L; Stio RE; Agati L; Modena MG; Genuini I; Fedele F; Gibson M
J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):529-35. PubMed ID: 19918189
[TBL] [Abstract][Full Text] [Related]
9. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
Thiele H; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Wiemer M; Kerber S; Kleinertz K; Eitel I; Desch S; Schuler G
Lancet; 2012 Mar; 379(9819):923-931. PubMed ID: 22357109
[TBL] [Abstract][Full Text] [Related]
10. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
[TBL] [Abstract][Full Text] [Related]
11. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
[TBL] [Abstract][Full Text] [Related]
12. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial.
Stone GW; Maehara A; Witzenbichler B; Godlewski J; Parise H; Dambrink JH; Ochala A; Carlton TW; Cristea E; Wolff SD; Brener SJ; Chowdhary S; El-Omar M; Neunteufl T; Metzger DC; Karwoski T; Dizon JM; Mehran R; Gibson CM;
JAMA; 2012 May; 307(17):1817-26. PubMed ID: 22447888
[TBL] [Abstract][Full Text] [Related]
13. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
Thiele H; Wöhrle J; Neuhaus P; Brosteanu O; Sick P; Prondzinsky R; Birkemeyer R; Wiemer M; Kerber S; Schuehlen H; Kleinertz K; Axthelm C; Zimmermann R; Rittger H; Braun-Dullaeus RC; Lauer B; Burckhardt W; Ferrari M; Bergmann MW; Hambrecht R; Schuler G;
Am Heart J; 2010 Apr; 159(4):547-54. PubMed ID: 20362711
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
[TBL] [Abstract][Full Text] [Related]
15. [Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial].
Galache Osuna JG; Sánchez-Rubio J; Calvo I; Diarte JA; Lukic A; Placer LJ
Rev Esp Cardiol; 2006 Jun; 59(6):567-74. PubMed ID: 16790200
[TBL] [Abstract][Full Text] [Related]
16. Rationale for intracoronary administration of abciximab.
Romagnoli E; Burzotta F; Trani C; Biondi-Zoccai GG; Giannico F; Crea F
J Thromb Thrombolysis; 2007 Feb; 23(1):57-63. PubMed ID: 17160551
[TBL] [Abstract][Full Text] [Related]
17. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
18. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.
Danzi GB; Sesana M; Capuano C; Mauri L; Berra Centurini P; Baglini R
Am J Cardiol; 2004 Jul; 94(1):35-9. PubMed ID: 15219505
[TBL] [Abstract][Full Text] [Related]
19. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts.
Barsness GW; Buller C; Ohman EM; Schechter E; Pucillo A; Taylor MA; Miller MJ; Reiner JS; Churchill D; Chandler AB; Gonzalez M; Smith J; Tommaso C; Berdan LG; Wildermann NM; Hasdai D; Holmes DR
Am Heart J; 2000 May; 139(5):824-9. PubMed ID: 10783216
[TBL] [Abstract][Full Text] [Related]
20. Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials.
Sun B; Liu Z; Yin H; Wang T; Chen T; Yang S; Jiang Z
Medicine (Baltimore); 2017 Oct; 96(40):e8223. PubMed ID: 28984776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
